CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Heterogeneity in tumor chromatin-doxorubicin binding revealed by in vivo fluorescence lifetime imaging confocal endomicroscopy

Open access

Abstract

We present an approach to quantify drug–target engagement using in vivo fluorescence endomicroscopy, validated with in vitro measurements. Doxorubicin binding to chromatin changes the fluorescence lifetime of histone-GFP fusions that we measure in vivo at single-cell resolution using a confocal laparo/endomicroscope. We measure both intra- and inter-tumor heterogeneity in doxorubicin chromatin engagement in a model of peritoneal metastasis of ovarian cancer, revealing striking variation in the efficacy of doxorubicin–chromatin binding depending on intra-peritoneal or intravenous delivery. Further, we observe significant variations in doxorubicin–chromatin binding between different metastases in the same mouse and between different regions of the same metastasis. The quantitative nature of fluorescence lifetime imaging enables direct comparison of drug–target engagement for different drug delivery routes and between in vitro and in vivo experiments. This uncovers different rates of cell killing for the same level of doxorubicin binding in vitro and in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04820-6

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Confocal micro-endoscope system. a Diagram shows the confocal endomicroscope (CEM) system. For time-domain FLIM, a Ti:Sapphire laser operating at 80 MHz is frequency-doubled to generate excitation light at 488 nm. A 720 nm short pass filter rejects the infrared fundamental wavelength at 976 nm. The excitation is introduced into the confocal excitation/imaging path via a 505 nm long pass dichroic beamsplitter and directed to a resonant scanner for rapid line scanning and a galvanometric mirror for frame scanning. The scanned excitation laser beam is focused onto a coherent fiber-optic bundle such that it sequentially addresses single cores in the fiber-optic bundle, which has a diameter of ~1 mm with ~30,000 cores. At the distal tip of the coherent fiber-optic bundle, a mini-objective lens of 2.6 mm diameter images each illuminated fiber core onto the sample plane and the fluorescence signal from the sample is imaged back onto the same core of the distal end of the fiber-optic bundle. This implements optically sectioned confocal imaging with the core serving as the confocal pinhole. At the proximal end of the fiber-optic bundle the fluorescence signal is descanned and focused onto a confocal aperture in front of a photon-counting photomultiplier. Photodetection events are recorded via a TCSPC card (B&H SPC830) that associates a photon arrival time relative to the phase of the scanning unit mirrors and arrival of the excitation laser pulses. Thus, histograms of photon arrival times are assigned to each image pixel and subsequently used to generate a fluorescence lifetime image. TCSPC count rates are ≤106 Hz. b Photograph of the confocal endomicroscope alongside a 20× multiphoton microscope objective (Carl Zeiss, objective Plan-Apochromat 20× /0.8, M27, model# 420650-9901-000), showing their relative size. c Fluorescence lifetime images of aqueous solutions (10 µM) of Rhodamine B (RB) and Rhodamine 6G (R6G) made using a conventional TCSPC FLIM microscope (MLSM) (Zeiss LSM-780 NDD multiphoton FLIM) and the CEM. The FLIM images are uniform as expected from a homogenous sample. d Fluorescence lifetime histograms corresponding to the FLIM images shown in c. The solid and dashed lines represent the MLSM and CEM FLIM data, respectively
Fig. 1 Confocal micro-endoscope system. a Diagram shows the confocal endomicroscope (CEM) system. For time-domain FLIM, a Ti:Sapphire laser operating at 80 MHz is frequency-doubled to generate excitation light at 488 nm. A 720 nm short pass filter rejects the infrared fundamental wavelength at 976 nm. The excitation is introduced into the confocal excitation/imaging path via a 505 nm long pass dichroic beamsplitter and directed to a resonant scanner for rapid line scanning and a galvanometric mirror for frame scanning. The scanned excitation laser beam is focused onto a coherent fiber-optic bundle such that it sequentially addresses single cores in the fiber-optic bundle, which has a diameter of ~1 mm with ~30,000 cores. At the distal tip of the coherent fiber-optic bundle, a mini-objective lens of 2.6 mm diameter images each illuminated fiber core onto the sample plane and the fluorescence signal from the sample is imaged back onto the same core of the distal end of the fiber-optic bundle. This implements optically sectioned confocal imaging with the core serving as the confocal pinhole. At the proximal end of the fiber-optic bundle the fluorescence signal is descanned and focused onto a confocal aperture in front of a photon-counting photomultiplier. Photodetection events are recorded via a TCSPC card (B&H SPC830) that associates a photon arrival time relative to the phase of the scanning unit mirrors and arrival of the excitation laser pulses. Thus, histograms of photon arrival times are assigned to each image pixel and subsequently used to generate a fluorescence lifetime image. TCSPC count rates are ≤106 Hz. b Photograph of the confocal endomicroscope alongside a 20× multiphoton microscope objective (Carl Zeiss, objective Plan-Apochromat 20× /0.8, M27, model# 420650-9901-000), showing their relative size. c Fluorescence lifetime images of aqueous solutions (10 µM) of Rhodamine B (RB) and Rhodamine 6G (R6G) made using a conventional TCSPC FLIM microscope (MLSM) (Zeiss LSM-780 NDD multiphoton FLIM) and the CEM. The FLIM images are uniform as expected from a homogenous sample. d Fluorescence lifetime histograms corresponding to the FLIM images shown in c. The solid and dashed lines represent the MLSM and CEM FLIM data, respectivelyCC BY · PubMed Central
Fig. 2 In vitro fluorescence lifetime measurement of doxorubicin binding to chromatin. a–c diagrams of possible interactions between doxorubicin and H1-EGFP chromatin. a doxorubicin (yellow dots) intercalation into DNA (blue regions represent the core histone optima and dark blue dashed lines represent DNA) brings it close to histone H1-EGFP, leading to energy transfer (orange stars). b GFP is not fused to histone H1 and is therefore not sufficiently close to DNA bound doxorubicin for energy transfer to occur. c doxorubicin is not binding DNA and therefore no energy transfer with histone H1-EGFP occurs. d in vitro multiphoton LSM fluorescence lifetime images of IGROV-1 cells transfected with the indicated constructs and exposed to 9 μM doxorubicin (scale bar is 210 µm). e Box plots of mean fluorescence lifetime values per cell corresponding to fluorescence lifetime images in d. Red and blue box plots represent measurements with and without incubation with doxorubicin for 3 h, respectively, for each construct. On each box plot, the central mark indicates the median, and the bottom and top edges of the box indicate the interquartile range (IQR). The box plot whiskers represent either 1.5 times the IQR or the maximum/minimum data point if they are within 1.5 times the IQR. For each construct, the data represented by the red and blue box plots were compared with an unpaired, unequal variances two-tailed t-test and the associated P-values are shown above each pair of box plots as described in the Methods section. With n = 1 biological replicates, the number of cells imaged for each expression type with & without (w&wo) DOX was 6&10 for cells expressing free EGFP, 12&30 for cells expressing H1-EGFP, and 8&6 for cells expressing H2-EGFP. Imaged cells for each construct expression and with&without DOX combination were sampled from a single well of a 6-well plate and all six combinations were seeded on the same 6-well plate
Fig. 2 In vitro fluorescence lifetime measurement of doxorubicin binding to chromatin. a–c diagrams of possible interactions between doxorubicin and H1-EGFP chromatin. a doxorubicin (yellow dots) intercalation into DNA (blue regions represent the core histone optima and dark blue dashed lines represent DNA) brings it close to histone H1-EGFP, leading to energy transfer (orange stars). b GFP is not fused to histone H1 and is therefore not sufficiently close to DNA bound doxorubicin for energy transfer to occur. c doxorubicin is not binding DNA and therefore no energy transfer with histone H1-EGFP occurs. d in vitro multiphoton LSM fluorescence lifetime images of IGROV-1 cells transfected with the indicated constructs and exposed to 9 μM doxorubicin (scale bar is 210 µm). e Box plots of mean fluorescence lifetime values per cell corresponding to fluorescence lifetime images in d. Red and blue box plots represent measurements with and without incubation with doxorubicin for 3 h, respectively, for each construct. On each box plot, the central mark indicates the median, and the bottom and top edges of the box indicate the interquartile range (IQR). The box plot whiskers represent either 1.5 times the IQR or the maximum/minimum data point if they are within 1.5 times the IQR. For each construct, the data represented by the red and blue box plots were compared with an unpaired, unequal variances two-tailed t-test and the associated P-values are shown above each pair of box plots as described in the Methods section. With n = 1 biological replicates, the number of cells imaged for each expression type with & without (w&wo) DOX was 6&10 for cells expressing free EGFP, 12&30 for cells expressing H1-EGFP, and 8&6 for cells expressing H2-EGFP. Imaged cells for each construct expression and with&without DOX combination were sampled from a single well of a 6-well plate and all six combinations were seeded on the same 6-well plateCC BY · PubMed Central
Fig. 3 In vitro fluorescence lifetime measurement of GFP bound to chromatin for range of doxorubicin concentrations. a Exemplar fluorescence lifetime images of IGROV-1 cells with stable expression of histone H1-EGFP treated with a range of doxorubicin concentrations (0, 0.18, 0.9, 1.8, 9, 18 µM) for 3 h then fixed, washed and imaged with the multiphoton LSM (scale bar is 120 µm). For each concentration 3 or more fields-of-view (containing a total of >100 nuclei) were acquired. b Exemplar fluorescence lifetime images of the same samples as in a but acquired with the CEM (scale bar is 120 µm). In a and b FLIM data was fitted to a single exponential decay model (as discussed in the Methods section). c Plot shows the mean lifetime of segmented nuclei averaged over the mean fluorescence lifetimes per segmented nucleus (i.e., average of values from pixel-wise fitting to a single exponential decay model within a single nucleus) for each doxorubicin concentration; d plot shows the intensity-weighted mean H1-EGFP fluorescence lifetimes obtained by global fitting across the entire dataset (as discussed in the Methods section) to a double exponential decay model with the long lifetime component fixed to the value obtained from cells expressing H1-EGFP when not treated with doxorubicin. For c and d black and magenta lines and circles represent the multiphoton LSM and CEM data, respectively. e plot shows only the globally fitted intensity-weighted mean H1-EGFP lifetime for the experimental CEM FLIM data (magenta lines and circles) together with simulations of the measured lifetime dependence on doxorubicin concentration (as discussed in Supplementary Note 1) assuming no FRET but a bleed through (BT) contribution from doxorubicin fluorescence (red line and circles) and H1-EGFP FRET with the BT contribution from doxorubicin fluorescence (blue line and circles). The solid blue and red lines represent the simulated intensity-weighted mean lifetime values based on the median cell-wise measured contribution from doxorubicin fluorescence in the CEM (see Supplementary Note 1). The dashed red and blue lines indicate simulated values based on the 25th and 75th percentiles of the measured contribution from doxorubicin fluorescence. The magenta and green lines (measured intensity-weighted mean lifetime values) show the median (solid lines and circles) and 25th and 75th (dashed lines) percentile values of the distribution across all H1-GFP expressing cells and GFP expressing cells, respectively
Fig. 3 In vitro fluorescence lifetime measurement of GFP bound to chromatin for range of doxorubicin concentrations. a Exemplar fluorescence lifetime images of IGROV-1 cells with stable expression of histone H1-EGFP treated with a range of doxorubicin concentrations (0, 0.18, 0.9, 1.8, 9, 18 µM) for 3 h then fixed, washed and imaged with the multiphoton LSM (scale bar is 120 µm). For each concentration 3 or more fields-of-view (containing a total of >100 nuclei) were acquired. b Exemplar fluorescence lifetime images of the same samples as in a but acquired with the CEM (scale bar is 120 µm). In a and b FLIM data was fitted to a single exponential decay model (as discussed in the Methods section). c Plot shows the mean lifetime of segmented nuclei averaged over the mean fluorescence lifetimes per segmented nucleus (i.e., average of values from pixel-wise fitting to a single exponential decay model within a single nucleus) for each doxorubicin concentration; d plot shows the intensity-weighted mean H1-EGFP fluorescence lifetimes obtained by global fitting across the entire dataset (as discussed in the Methods section) to a double exponential decay model with the long lifetime component fixed to the value obtained from cells expressing H1-EGFP when not treated with doxorubicin. For c and d black and magenta lines and circles represent the multiphoton LSM and CEM data, respectively. e plot shows only the globally fitted intensity-weighted mean H1-EGFP lifetime for the experimental CEM FLIM data (magenta lines and circles) together with simulations of the measured lifetime dependence on doxorubicin concentration (as discussed in Supplementary Note 1) assuming no FRET but a bleed through (BT) contribution from doxorubicin fluorescence (red line and circles) and H1-EGFP FRET with the BT contribution from doxorubicin fluorescence (blue line and circles). The solid blue and red lines represent the simulated intensity-weighted mean lifetime values based on the median cell-wise measured contribution from doxorubicin fluorescence in the CEM (see Supplementary Note 1). The dashed red and blue lines indicate simulated values based on the 25th and 75th percentiles of the measured contribution from doxorubicin fluorescence. The magenta and green lines (measured intensity-weighted mean lifetime values) show the median (solid lines and circles) and 25th and 75th (dashed lines) percentile values of the distribution across all H1-GFP expressing cells and GFP expressing cells, respectivelyCC BY · PubMed Central
Fig. 4 Intravital image acquisition and analysis. a Images show examples of two nodules being imaged. The white arrow indicates a nodule attached to the intestine and the yellow arrow indicates a tumor mass growing into the peritoneal wall. b–e Schematic of analysis workflow for in vivo CEM FLIM of IGROV-1 H1-GFP labeled tumors in mouse model. Raw integrated intensity images produced by CEM at 8.5 Hz (b) are aligned using template matching (example template shown with green box in b) based on normalized cross-correlation. The alignment quality is periodically degraded by breathing (example shown in c) and frames that are severely affected by motion are rejected; the remaining frames are combined following alignment to generate high signal-to-noise image data (as shown in d) that are suitable for FLIM analysis. The inset image with a yellow border in d shows the same 10 second acquisition but without applying the motion compensating alignment algorithm. f–h show how increasing the number of frames that are combined increases the accuracy of fitting to a single exponential decay model. As frame accumulations are increased from 5 to 85 frames, FIFO FLIM integration times increase from sub-second to 10 s and the number of photons per pixel increases. This is associated with a decrease in the residuals following fitting of the FLIM data to the single exponential decay model. i image segmentation was used to calculate lifetimes on a nucleus by nucleus basis: a locally adaptive thresholding routine was used to form an initial segmentation guess and then erosion and dilation steps were used to separate contiguous nuclei, followed by application of the watershed.m function in MATLAB. The segmentation masks were then loaded into FLIMfit along with the raw TCSPC FIFO data. Integrated intensity image from aligned raw TCSPC FIFO data, watershed segmentation binary image, and FLIMfit graphical user interface are shown in j, k, and l, respectively
Fig. 4 Intravital image acquisition and analysis. a Images show examples of two nodules being imaged. The white arrow indicates a nodule attached to the intestine and the yellow arrow indicates a tumor mass growing into the peritoneal wall. b–e Schematic of analysis workflow for in vivo CEM FLIM of IGROV-1 H1-GFP labeled tumors in mouse model. Raw integrated intensity images produced by CEM at 8.5 Hz (b) are aligned using template matching (example template shown with green box in b) based on normalized cross-correlation. The alignment quality is periodically degraded by breathing (example shown in c) and frames that are severely affected by motion are rejected; the remaining frames are combined following alignment to generate high signal-to-noise image data (as shown in d) that are suitable for FLIM analysis. The inset image with a yellow border in d shows the same 10 second acquisition but without applying the motion compensating alignment algorithm. f–h show how increasing the number of frames that are combined increases the accuracy of fitting to a single exponential decay model. As frame accumulations are increased from 5 to 85 frames, FIFO FLIM integration times increase from sub-second to 10 s and the number of photons per pixel increases. This is associated with a decrease in the residuals following fitting of the FLIM data to the single exponential decay model. i image segmentation was used to calculate lifetimes on a nucleus by nucleus basis: a locally adaptive thresholding routine was used to form an initial segmentation guess and then erosion and dilation steps were used to separate contiguous nuclei, followed by application of the watershed.m function in MATLAB. The segmentation masks were then loaded into FLIMfit along with the raw TCSPC FIFO data. Integrated intensity image from aligned raw TCSPC FIFO data, watershed segmentation binary image, and FLIMfit graphical user interface are shown in j, k, and l, respectivelyCC BY · PubMed Central
Fig. 5 Comparison of intravenous and intra-peritoneal delivery routes. CEM FLIM data from murine cancer model based on IGROV-1 cells injected intraperitoneally and allowed to grow into tumors over 14–21 days. Subsequently mice were treated with 5 mg kg−1 doses of doxorubicin by intraperitoneal (IP) or intravenous (IV) injection. At 1.5, 3, and 24 h post dosing, repeat models underwent minor surgery to expose tumors for imaging with the CEM. a scatter plots of intensity-weighted mean H1-EGFP fluorescence lifetime against mean intensity for each for each cell nucleus from control mice (black), mice that underwent IP delivery of drug (green), and mice that underwent IV delivery of drug (red). The drug incubation times 1.5, 3, and 24 h are shown above each plot in a for doxorubicin-treated mice. b–h Histograms show the distribution of calculated population fraction of FRETing H1-EGFP with higher values indicating increasing doxorubicin binding to chromatin; i–o Histograms show intracellular doxorubicin concentration estimated according to in vitro calibration as discussed in Supplementary Note 1. Individual mice (M) are represented in each histogram by different colors. Control mice distributions are shown in b, i and treated mice distributions are shown in c–h, j–o. Biological replicates for each condition are as follows: n = 5 control mice; n = 4 IP mice at 1.5 h; n = 3 mice at IV 1.5 h; n = 5 mice at IP 3 h; n = 6 mice at IV 3 h; n = 4 mice at IP 24 h; n = 3 mice at IV 24 h
Fig. 5 Comparison of intravenous and intra-peritoneal delivery routes. CEM FLIM data from murine cancer model based on IGROV-1 cells injected intraperitoneally and allowed to grow into tumors over 14–21 days. Subsequently mice were treated with 5 mg kg−1 doses of doxorubicin by intraperitoneal (IP) or intravenous (IV) injection. At 1.5, 3, and 24 h post dosing, repeat models underwent minor surgery to expose tumors for imaging with the CEM. a scatter plots of intensity-weighted mean H1-EGFP fluorescence lifetime against mean intensity for each for each cell nucleus from control mice (black), mice that underwent IP delivery of drug (green), and mice that underwent IV delivery of drug (red). The drug incubation times 1.5, 3, and 24 h are shown above each plot in a for doxorubicin-treated mice. b–h Histograms show the distribution of calculated population fraction of FRETing H1-EGFP with higher values indicating increasing doxorubicin binding to chromatin; i–o Histograms show intracellular doxorubicin concentration estimated according to in vitro calibration as discussed in Supplementary Note 1. Individual mice (M) are represented in each histogram by different colors. Control mice distributions are shown in b, i and treated mice distributions are shown in c–h, j–o. Biological replicates for each condition are as follows: n = 5 control mice; n = 4 IP mice at 1.5 h; n = 3 mice at IV 1.5 h; n = 5 mice at IP 3 h; n = 6 mice at IV 3 h; n = 4 mice at IP 24 h; n = 3 mice at IV 24 hCC BY · PubMed Central
Fig. 6 Intra-nodule and regional heterogeneity in doxorubicin chromatin binding. CEM FLIM data from murine cancer model based on IGROV-1 cells with mice treated with 5 mg kg−1 doxorubicin doses by IP injection. a, b, c show intra-nodule variation in normalized histograms of H1-GFP FRETing population fractions 3 h after IP delivery of drug, together with histograms of estimated intracellular doxorubicin concentration, d, e, f for three fields-of-view of a tumor nodule (T1) on the peritoneal wall, a tumor nodule (T2) on the spleen, and a second tumor nodule (T3) on the spleen in the same mouse, respectively. g, h, i show the corresponding maps of the H1-EGFP FRETing population fraction (where color scale from blue to red spans 0–1). j shows normalized histograms for H1-GFP FRETing population fractions and k shows estimated intracellular doxorubicin concentration for 6 fields-of-view from a single nodule in a control mouse and l shows the corresponding map of the H1-EGFP FRETing population fractions. m shows normalized histograms for H1-GFP FRETing population fractions and n shows estimated intracellular doxorubicin concentration for 6 fields-of-view from a single nodule in a mouse, 3 h after intra-peritoneal delivery of 5 mg kg−1 doxorubicin and o shows the corresponding map of the H1-EGFP FRETing population fraction. For all images the scale bar is 120 μm
Fig. 6 Intra-nodule and regional heterogeneity in doxorubicin chromatin binding. CEM FLIM data from murine cancer model based on IGROV-1 cells with mice treated with 5 mg kg−1 doxorubicin doses by IP injection. a, b, c show intra-nodule variation in normalized histograms of H1-GFP FRETing population fractions 3 h after IP delivery of drug, together with histograms of estimated intracellular doxorubicin concentration, d, e, f for three fields-of-view of a tumor nodule (T1) on the peritoneal wall, a tumor nodule (T2) on the spleen, and a second tumor nodule (T3) on the spleen in the same mouse, respectively. g, h, i show the corresponding maps of the H1-EGFP FRETing population fraction (where color scale from blue to red spans 0–1). j shows normalized histograms for H1-GFP FRETing population fractions and k shows estimated intracellular doxorubicin concentration for 6 fields-of-view from a single nodule in a control mouse and l shows the corresponding map of the H1-EGFP FRETing population fractions. m shows normalized histograms for H1-GFP FRETing population fractions and n shows estimated intracellular doxorubicin concentration for 6 fields-of-view from a single nodule in a mouse, 3 h after intra-peritoneal delivery of 5 mg kg−1 doxorubicin and o shows the corresponding map of the H1-EGFP FRETing population fraction. For all images the scale bar is 120 μmCC BY · PubMed Central
Fig. 7 Differential doxorubicin efficacy in vivo and in vitro. a Chart shows effect of 0, 0.18, 0.9, 1.8, 9, and 18 μM doxorubicin treatment on the viability of IGROV-1 stably expressing luciferase in vitro. Viability was assessed by luciferase activity in 24-well plate (1 × 105 cells well−1). Each data point represents the average intensity relative to that for 0 μM plotted at time = 0 h. The error bars represent the s.d. for n = 3 biological replicates i.e., three 24-well plates. b–g images show the effect of doxorubicin on IGROV-1 tumor burden in vivo. b–d show luciferase imaging of mice immediately (0 h) following control (b), intraperitoneal (c) or intravenous (d) injection with control PBS or 5 mg kg−1 doxorubicin. e–g show the corresponding sets of mice 48 h postinjection. Biological replicates of n = 4 mice were used for each luciferase imaging condition
Fig. 7 Differential doxorubicin efficacy in vivo and in vitro. a Chart shows effect of 0, 0.18, 0.9, 1.8, 9, and 18 μM doxorubicin treatment on the viability of IGROV-1 stably expressing luciferase in vitro. Viability was assessed by luciferase activity in 24-well plate (1 × 105 cells well−1). Each data point represents the average intensity relative to that for 0 μM plotted at time = 0 h. The error bars represent the s.d. for n = 3 biological replicates i.e., three 24-well plates. b–g images show the effect of doxorubicin on IGROV-1 tumor burden in vivo. b–d show luciferase imaging of mice immediately (0 h) following control (b), intraperitoneal (c) or intravenous (d) injection with control PBS or 5 mg kg−1 doxorubicin. e–g show the corresponding sets of mice 48 h postinjection. Biological replicates of n = 4 mice were used for each luciferase imaging conditionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Lewis, J. P. Fast template matching. Vis. Interface 95, 120–123 (1995).

Cited by

See all 54

Metadata

Authors
Sparks, H., Kondo, H., Hooper, S., Munro, I., Kennedy, G., Dunsby, C., French, P., & Sahai, E.
Affiliations
  • The Francis Crick Institute (GB)
  • Imperial College London (GB)
Corresponding author
  • Dunsby, Christopher
  • French, Paul
  • Sahai, Erik
Venue
Nature Communications
Published
2018-07-09
Volume
9
Issue
1
Pages
2662-2662
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2810921156
Cited by
54
References
41
Citations by year
2026: 5 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 9 · 2021: 11 · 2020: 6 · 2019: 6
FWCI
3.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Cancer Research UK (FC001144)
  • Medical Research Council (FC001144)
  • Wellcome Trust (FC001144)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Advanced Fluorescence Microscopy Techniques
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Optical Imaging and Spectroscopy Techniques
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
doxorubicin, chromatin binding, drug-target engagement, fluorescence lifetime imaging, confocal laser endomicroscopy, ovarian cancer, peritoneal carcinomatosis, tumor heterogeneity, drug delivery routes, single-cell imaging
MeSH terms
Animals, Antibiotics, Antineoplastic, Chromatin, Doxorubicin, Fluorescence, Humans, Mice, Nude, Neoplasms, Drug Delivery Systems, Microscopy, Confocal, Xenograft Model Antitumor Assays, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Heterogeneity in tumor chromatin-doxorubicin binding revealed by in vivo fluorescence lifetime imaging confocal endomicroscopy. https://app.cochat.ai/papers/10.1038/s41467-018-04820-6
The paper
Sparks, H., Kondo, H., Hooper, S., Munro, I., Kennedy, G., Dunsby, C., French, P., & Sahai, E. (2018). Heterogeneity in tumor chromatin-doxorubicin binding revealed by in vivo fluorescence lifetime imaging confocal endomicroscopy. Nature Communications. https://doi.org/10.1038/s41467-018-04820-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.